- Home
- CCIF vs INMB Comparison
CCIF vs INMB Comparison
Compare CCIF & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | INMB |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 64.7M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CCIF | INMB |
|---|---|---|
| Price | $2.71 | $2.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 107.4K | ★ 339.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $2.57 | $1.09 |
| 52 Week High | $5.95 | $2.50 |
Technical Indicators
Market Signals| Indicator | CCIF | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 58.65 |
| Support Level | $2.57 | $1.16 |
| Resistance Level | $2.95 | $2.50 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.64 | 52.51 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.